|| List of recent Nucleotide-related patents
| Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same|
Provided are methods of increasing tolerance of a plant to abiotic stress, and/or increasing biomass, growth rate, vigor and/or yield of a plant. The methods are effected by expressing within the plant an exogenous polynucleotide encoding a polypeptide comprising an amino acid sequence at least 90% homologous to the amino acid sequence selected from the group consisting of seq id nos:201, 207, 212, 202-206, 208-211, 213-391, 1655, 961-1529, and 1660-1663.
| Expression of isomers of sucrose increases seed weight, seed number and/or seed size|
The present invention provides expression vectors comprising polynucleotides encoding chimeric sucrose isomerases, and methods of using the same. In addition, transgenic plants expressing said chimeric sucrose isomerases are provided.
| Sorghum maturity gene and uses thereof in modulating photoperiod sensitivity|
Compositions relating to the sorghum maturity gene 1 (ma1) and expression control sequences and methods of use thereof are provided. The compositions can be used to modulate flowering and photoperiod sensitivity in a plant.
| Drought tolerant plants and related constructs and methods involving genes encoding zinc-finger (c3hc4-type ring finger) family polypeptides|
Isolated polynucleotides and polypeptides and recombinant dna constructs useful for conferring drought tolerance, compositions (such as plants or seeds) comprising these recombinant dna constructs, and methods utilizing these recombinant dna constructs. The recombinant dna construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a zinc-finger (c3hc4-type ring finger) family polypeptide..
| Use of aldh7 for improved stress tolerance|
The present invention relates to the field of plant molecular biology, more particularly to the regulation of genes that increase drought tolerance and yield. Provided herein are methods finding use in agriculture for increasing drought tolerance in dicot and monocot plants.
| Stress responsive expression|
The present invention relates to the identification of transcriptional control sequences that are active in plants in response to stress. Accordingly, methods for effecting stress responsive expression of a nucleotide sequence of interest in a plant are provided, the methods including expressing the nucleotide sequence of interest operably connected to a transcriptional control sequence which is stress inducible in the plant, wherein the nucleotide sequence of interest is heterologous with respect to the transcriptional control sequence.
| Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency|
The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake.
| Ancestral-specific reference genomes and uses thereof|
Ancestry has a significant impact on the major and minor alleles found in each nucleotide position within the genome. Due to mechanisms of inheritance, ancestral-specific information contained within the genome is conserved within members of an ancestry.
| Snp detection by melt curve clustering|
Systems, methods and apparatus for an automated analysis of a collection of melt curves is provided. The analysis can identify certain characteristics of double stranded nucleotide sequences (e.g.
| Method for deblocking of labeled oligonucleotides|
The invention relates to a process for deblocking substantially a blocked, detectably labeled oligonucleotide by contacting the blocked detectably labeled oligonucleotide with an effective amount of a nucleophilic amino compound under conditions that result in substantial deblocking of the oligonucleotide, thereby giving the substantially deblocked oligonucleotide.. .
| Oligonucleotide primers, probes, kits and methods for detection of cytomegalovirus|
Amplification primers and methods for specific amplification and detection of a cmv target are disclosed. The primer-target binding sequences are useful for amplification and detection of the cmv target in a variety of amplification and detection reactions..
| Compositions and methods for treatment of ear disorders|
The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject..
| Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences|
The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named iss-n1 (for “intronic splicing silencer”), located in the smn2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the smn2 iss-n1 site in the smn2 pre-mrna, thereby modulating the splicing of smn2 pre-mrna to include exon 7 in the processed transcript.
| Chemical modification motifs for mirna inhibitors and mimetics|
The present invention provides polynucleotides having chemistry patterns that provide for improved stability, potency, and/or toxicity relative to their use as mirna inhibitors or mirna mimetics. The invention further provides pharmaceutical compositions and formulations comprising the polynucleotides, and methods for treating patients having a condition associated with mirna or mrna expression..
| Methods for using semaphorin polypeptides|
The present invention provides uses and methods of using a sema3e polypeptide and a sema3e polynucleotide encoding a sema3e polypeptide. The methods include decreasing airway remodeling in a subject, treating asthma in a subject, treating a subject having, or at risk of having, acute asthma, and reducing inflammation of a subject's airway.
| Template directed split and mix synthesis of small molecule libraries|
The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule l to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c)..
| Method of preparing libraries of template polynucleotides|
The present invention relates to a method for preparing a library of template polynucleotides and use thereof in methods of solid-phase nucleic acid amplification. More specifically, the invention relates to a method for preparing a library of template polynucleotides that have common sequences at their 5′ ends and at their 3′ ends..
| Tagged oligonucleotides and their use in nucleic acid amplification methods|
The present invention provides nucleic acid amplification systems and methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results..
| Kits and methods for assessing oxidative stress|
The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans.
| Mouse cell line authentication|
A multiplex polymerase chain reaction assay that targets nine tetranucleotide short tandem repeat (str) markers in the mouse genome. Unique profiles were obtained from seventy-two mouse samples that were used to determine the allele distribution for each str marker.
| Systems and methods to detect rare mutations and copy number variation|
The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference.
| Methods for fragmentation and labeling of nucleic acids|
The invention provides methods, compositions, and kits for fragmentation and labeling of nucleic acids. More particularly, the invention relates to methods for fragmentation of nucleic acids to produce fragments with 3′ end hydroxyl groups within a desired size range.
| Dicarboxylic acid production in a recombinant yeast|
The present invention relates to a recombinant yeast comprising a nucleotide sequence encoding a heterologous enzyme that catalyses the conversion of malic acid to fumaric acid. The invention further relates to a process for the production of a dicarboxylic acid wherein the yeast according to the present invention is used..
| Novel glycoside hydrolases from thermophlic fungi|
The present invention relates to isolated polypeptides having cellulolytic activity or hemicellulolytic activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
| Stacking nucleic acid and methods for use thereof|
The present invention provides a novel modified oligonucleotide monomer useful in molecular biological techniques such as capture and/or detection of nucleic acids, amplification of nucleic acids and sequencing of nucleic acids. The modified oligonucleotide monomer comprises an intercalator that can intercalate into an antiparallel duplex from the major groove..
| Nucleotides and primers with removable blocking groups|
Provided herein is a method of amplifying nucleic acids using a plurality of modified nucleotides one or more of the nucleotides comprising a 3′ blocking group. Also provided is a method of amplifying nucleic acids using oligonucleotide primers one or both of the primers comprising a 3′ blocking group on one or more of the nucleotides of the primers..
| Polypeptides having cellobiohydrolase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having cellobiohydrolase activity, catalytic domains, and cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains, and cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, or cellulose binding domains..
| Targeted deletion of cellular dna sequences|
Disclosed herein are methods and compositions for targeted deletion of double-stranded dna. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same.
| Cldn5 mini-promoters|
Isolated polynucleotides comprising a cldn5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
| Analyzing messenger rna and micro rna in the same reaction mixture|
The present teachings provide methods, compositions, and kits for performing primer extension reactions on at least two target polynucleotides in the same reaction mixture. In some embodiments, a reverse transcription reaction is performed on a first target polynucleotide with a hot start primer comprising a self-complementary stem and a loop, and extension products form at high temperatures but extension products form less so at low temperatures since the self-complementary stem of the hot start primer prevents hybridization of the target specific region to the target.
| Phospholink nucleotides for sequencing applications|
The present invention provides labeled phospholink, nucleotides that can be used in place of naturally occurring nucleotide triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions and various analyses based thereon, including dna sequencing, single base identification, hybridization assays, and others.. .
| Methods and compositions for labeling nucleic acids|
The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. Certain methods are provided that include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label.
| Fuel cell, method for producing fuel cell, electronic apparatus, nicotinamide adenine dinucleotide-immobilized electrode, nicotinamide adenine dinucleotide-immobilized carrier, enzyme reaction utilization device, protein-immobilized electrode and protein-immobilized carrier|
A biofuel cell having a structure in which a positive electrode and a negative electrode face each other via a proton conductor, the biofuel cell configured so that an enzyme is used to extract electrons from a fuel, wherein the negative electrode is configured from an electrode including carbon and/or an inorganic compound having pores with a size of 2 nm or more and 100 nm or less on the surface, nicotinamide adenine dinucleotide and/or a derivative thereof being immobilized on the carbon and/or the inorganic compound. A carbon particle, a carbon sheet, or carbon fiber is used as the carbon..
| Perfluorinated compounds for the non-viral transfer of nucleic acids|
The invention relates to a compound of general formula (i): a-b-c(f, g′)-d-e-f-g-a′ or a structure of general formula (ii): a-b-c-(f′, g′)-d-b-e-f-g-a′ (ii), wherein -a is at least one molecule selected from the group of the perfluorocarbons (pfcs), perfluorinated silicon compounds, and/or further perfluorinated compounds, -b is at least one predetermined breaking point in the form of a physically, chemically, or enzymatically severable bond, -c is absent or at least one linker molecule, -d is absent or at least one spacer molecule, -e is at least one molecule selected from the group containing nucleobases, nucleosides, nucleotides, oligonucleotides, nucleic, acids, modified nucleobases, modified nucleosides, modified nucleotides, modified oligonucleotides, modified nucleic acids, monomers of peptide nucleic acids, oligomers or peptide nucleic acids and peptide nucleic acids or other nucleic acid analogs, -f, f′ is absent or at least one ligand, -g, g′ is absent or at least one marker molecule, -a′ is absent or has the meaning of a, and wherein the compounds i), ii), iii), iv), v), vi) are excluded. The invention farther relates to the use of said compound for the non-viral transfer of molecule e into a cell, to a pharmaceutical composition containing said compound, and to the use of said pharmaceutical composition..
| Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines|
The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is gap-dmorie..
| Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof|
A vaccine comprising an immunologically effective amount of recombinant modified vaccinia ankara (rmva) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified h5 (mh5) promoter operably linked to a dna sequence encoding a heterologous foreign protein antigen, wherein the expression of said dna sequence is under the control of the mh5 promoter; b) generating rmva virus by transfecting one or more plasmid vectors obtained from step a) into wild type mva virus; c) identifying rmva virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rmva virus strain identified by step d); and f) purifying the rmva viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (cmv) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of immediate-early gene-1 or immediate-early gene-2 (iefusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine..
| Anti-kit antibodies and uses thereof|
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation.
| Novel epitope for switching to th1 cell and use thereof|
The present invention relates to a novel epitope that converts t cell to type 1 helper t (th1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (seq id no.
| Methods for treating melanoma|
Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a dll4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human dll4) to a subject.
| Treatment for ige-mediated disease|
The invention provides an endos polypeptide, or a polynucleotide encoding an endos polypeptide, for use in a method for treating or preventing a disease or condition mediated by ige antibodies.. .